as multi-institutional prospective observational study (UMIN000025112). All plasma samples were assessed by cobas test. Additionally, we retrospectively reviewed patients who had underwent cobas test in plasma after resistance to G/E as control arm. In all patients, patient characteristics, efficacy of EGFR-TKIs, and T790M status in plasma and tissue were reviewed. Results: Fifty-one patients with resistance to afatinib were enrolled in the prospective observation study. Of these patients, 35 patients were treated with afatinib as first-line setting. Fourteen patients (40%) had EGFR driver mutation in plasma, and only 3 patients (7.3%) had T790M in plasma. To compare the detection rate of EGFR driver and T790M mutation in plasma between patients treated with G/E than with afatinib, we selected 38 patients who were treated G/E as first-line setting and underwent plasma assay after resistance to G/E. There was no difference in the detection of EGFR driver mutation and T790M mutation in patients treated with G/E than afatinib ([EGFR driver mutation]: 52.6% vs 40.0%, p¼0.28 and [T790M]: 23.7% vs. 8.6%, p¼0.08). However, on patients with EGFR driver mutation positive in plasma (N¼34), the T790M detection in plasma was significantly higher in patients treated with G/E than those with afatinib (45.0% vs. 14.3%, p¼0.05). On the other hands, in 42 patients who underwent tissue analysis for T790M mutation, there was no significant difference in the frequency of T790M mutation in tissue by rebiopsy between two groups (G/E vs afatinib: 20.7% vs 23.7%, p¼0.77). Conclusion: CfDNA analysis for T790M mutation by cobas test in patients treated with afatinib could be insufficient compared with those with firstgeneration EGFR-TKIs (G and E (Cbl-b) is an important gene for T cell immunity regulation. We sought to understand the involvement of PD-L1 and Cbl-b expressions in NSCLC. Method: With immunohistochemistry (IHC), we investigated the expression of PD-L1 and Cbl-b in 165 patients with stage IeIII NSCLC. Correlations between PD-L1，Cbl-b and patient prognoses were analyzed. We further explored some basic researches. Cbl-b was knocked down by lentivirus expressing siRNA against Cbl-b in A549 cells (A549-KD cells). Inhibition of cancer cell proliferation, cell cycle arrest, and apoptosis were detected. Cbl-b, PD-L1, and Ki-67 protein levels were also tested by Western blot. Results: Among the NSCLC patients, 72.7% of them were positive for PD-L1 staining in tumor cells, while that for Cbl-b was 38.8%. The percentage of Cbl-b-positive cells was significantly correlated with OS (overall survival) (log-rank test, P ¼ 0.038) but that of PD-L1-positive cells was not (Fig-1) . A549-KD cells, proliferation was inhibited, the cell cycle was arrested, and apoptosis was increased. Moreover, PD-L1 and Ki-67 expressions were downregulated (Fig-2) . Conclusion: The percentage of Cbl-b-positive cells in NSCLC was significantly correlated with OS. In A549-KD, down regulation of PD-L1 and other anti-tumor effects were detected, which suggesting that Cbl-b might be involved in the PD-1/PD-L1 signaling pathway.
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